Junlin Lu
Impact in
-
- Cancer-related molecular mechanisms research
- Pharmacology top 10%
- Pharmacological Effects of Natural Compounds
Papers in
-
- Kidney Stones and Urolithiasis Treatments 10
- Ferroptosis and cancer prognosis 3
- Oncology 8
- CAR-T cell therapy research 3
- Cancer Immunotherapy and Biomarkers 3
- Co-authors
- Shaogang Wang (19 shared papers)Qi‐Dong Xia (17 shared papers)Yang Xun (14 shared papers)Cong Li (10 shared papers)Jia Hu (8 shared papers)Xu Chen (8 shared papers)Tianxin Lin (6 shared papers)Hongjin Wang (4 shared papers)
- Journals
- Disease Markers (2 papers)Frontiers in Cell and Developmental Biology (2 papers)Frontiers in Medicine (2 papers)Nature Communications (2 papers)Advanced Materials (2 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Junlin Lu
35 papers receiving 899 citations
Junlin Lu's Hit Papers
Peers
Comparison fields: 5 of 88
- Cancer Research 125
- Pharmacology 61
- Pulmonary and Respiratory Medicine 197
- Complementary and alternative medicine 39
- Molecular Biology 304
Countries citing papers authored by Junlin Lu
This map shows the geographic impact of Junlin Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junlin Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junlin Lu more than expected).
Fields of papers citing papers by Junlin Lu
This network shows the impact of papers produced by Junlin Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junlin Lu. The network helps show where Junlin Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Junlin Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 185 | |
| 2 | NAT10 Drives Cisplatin Chemoresistance by Enhancing ac4C-Associated DNA Repair in Bladder Cancer Hit paper breakdown → | 2023 | 162 |
| 3 | 2023 | 98 | |
| 4 | 2015 | 76 | |
| 5 | 2020 | 50 | |
| 6 | 2023 | 36 | |
| 7 | 2024 | 34 | |
| 8 | 2020 | 34 | |
| 9 | 2022 | 25 | |
| 10 | 2020 | 23 | |
| 11 | 2020 | 21 | |
| 12 | 2022 | 19 | |
| 13 | 2025 | 15 | |
| 14 | 2020 | 14 | |
| 15 | 2021 | 13 | |
| 16 | 2022 | 13 | |
| 17 | 2021 | 11 | |
| 18 | 2021 | 8 | |
| 19 | 2025 | 8 | |
| 20 | 2022 | 7 |
About Junlin Lu
Junlin Lu is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Biotechnology, Surgery and Immunology, having authored 37 papers that have together received 911 indexed citations. Recurring topics across this work include Kidney Stones and Urolithiasis Treatments (10 papers), Bladder and Urothelial Cancer Treatments (7 papers), Cancer Research and Treatments (4 papers), CAR-T cell therapy research (3 papers), Ferroptosis and cancer prognosis (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Ubiquitin and proteasome pathways (2 papers) and Nanoplatforms for cancer theranostics (2 papers). The work is most often cited by research in Cancer Research (125 citations), Pharmacology (61 citations), Pulmonary and Respiratory Medicine (197 citations), Complementary and alternative medicine (39 citations) and Molecular Biology (304 citations). Junlin Lu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Shaogang Wang, Qi‐Dong Xia, Yang Xun, Cong Li, Jia Hu, Xu Chen, Tianxin Lin, Hongjin Wang, Ming Xing Huang and Yuchao Lu. Their work appears in journals such as Disease Markers, Frontiers in Cell and Developmental Biology, Frontiers in Medicine, Nature Communications and Advanced Materials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.